Nicholas Investment Partners LP Takes $1.62 Million Position in Olema Pharmaceuticals, Inc. $OLMA

Nicholas Investment Partners LP acquired a new position in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) during the fourth quarter, Holdings Channel.com reports. The institutional investor acquired 64,757 shares of the company’s stock, valued at approximately $1,619,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. EverSource Wealth Advisors LLC grew its position in Olema Pharmaceuticals by 9,476.9% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,245 shares of the company’s stock worth $31,000 after acquiring an additional 1,232 shares during the last quarter. Torren Management LLC acquired a new position in Olema Pharmaceuticals during the 4th quarter worth about $44,000. Fideuram Intesa Sanpaolo Private Banking S.P.A. acquired a new position in Olema Pharmaceuticals during the 4th quarter worth about $88,000. Nisa Investment Advisors LLC lifted its holdings in Olema Pharmaceuticals by 14.5% during the 4th quarter. Nisa Investment Advisors LLC now owns 3,764 shares of the company’s stock worth $94,000 after buying an additional 477 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in Olema Pharmaceuticals by 44.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,822 shares of the company’s stock worth $96,000 after buying an additional 1,169 shares during the period. Institutional investors own 91.78% of the company’s stock.

Analysts Set New Price Targets

OLMA has been the topic of several recent research reports. JPMorgan Chase & Co. lifted their target price on Olema Pharmaceuticals from $55.00 to $58.00 and gave the stock an “overweight” rating in a report on Wednesday, March 18th. Wall Street Zen raised Olema Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Monday, April 27th. The Goldman Sachs Group cut their target price on Olema Pharmaceuticals from $38.00 to $27.00 and set a “buy” rating on the stock in a report on Wednesday, March 18th. Jefferies Financial Group initiated coverage on Olema Pharmaceuticals in a report on Thursday, March 19th. They set a “buy” rating and a $40.00 target price on the stock. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Olema Pharmaceuticals in a report on Friday, May 22nd. Eleven analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Olema Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $44.10.

Olema Pharmaceuticals Stock Up 1.2%

Shares of NASDAQ:OLMA opened at $9.87 on Friday. The company has a market capitalization of $862.14 million, a price-to-earnings ratio of -4.89 and a beta of 1.98. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.88 and a quick ratio of 10.88. The business’s 50-day moving average is $13.96 and its 200-day moving average is $20.57. Olema Pharmaceuticals, Inc. has a 1 year low of $3.89 and a 1 year high of $36.26.

Olema Pharmaceuticals (NASDAQ:OLMA) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.52) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.52). Equities research analysts predict that Olema Pharmaceuticals, Inc. will post -2.16 earnings per share for the current year.

Olema Pharmaceuticals Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.